Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China (vol 9, 946399, 2022)

被引：0
|
作者：
Jiang, Yaohui [1 ]
Xie, Jun [1 ]
机构：
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Cardiol,Med Sch, Nanjing, Peoples R China
来源：
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2023年 / 10卷
关键词：
empagliflozin; heart failure with preserved ejection fraction; cost-effectiveness analysis; China; pharmaco economic;
D O I：
10.3389/fcvm.2023.1205721
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China
    Jiang, Yaohui
    Xie, Jun
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [2] Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
    Yake Lou
    Tianyang Hu
    Jing Huang
    [J]. American Journal of Cardiovascular Drugs, 2023, 23 : 47 - 57
  • [3] Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China
    Lou, Yake
    Hu, Tianyang
    Huang, Jing
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (01) : 47 - 57
  • [4] Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
    Low, J. Z.
    Ong, S. C.
    Linden, S.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 393
  • [5] Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
    Ong, Siew Chin
    Low, Joo Zheng
    Linden, Stephan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
    Zhou, Jennifer
    Liew, Danny
    Kaye, David M.
    Zoungas, Sophia
    Stub, Dion
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (10): : E008638
  • [7] Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction
    Zheng, Jimmy
    Parizo, Justin T.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA INTERNAL MEDICINE, 2022, 182 (12) : 1278 - 1288
  • [8] Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
    Lin, Xiaohui
    Lin, Minhua
    Liu, Maobai
    Huang, Weiying
    Nie, Xuekun
    Chen, Zichun
    Zheng, Bin
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1588 - 1597
  • [9] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [10] COST-EFFECTIVENESS OF MEDICAL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
    Truong, Katie
    Dixit, Neal
    Vaduganathan, Muthiah
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 622 - 622
12345